Photobiomodulation delivered with the Valeda light delivery system demonstrated sustained vision improvements at 24 months in patients with dry age-related macular degeneration, according to a press release from LumiThera.
The LIGHTSITE III clinical trial investigated the treatment in 100 patients with early to intermediate dry AMD at 10 U.S. retinal centers, with a primary efficacy endpoint of best corrected visual acuity. Eighty percent of patients completed the trial, and there were minimal safety risks and high patient compliance at the 24-month mark.
Ninety-one eyes were randomly assigned